Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 240

Sort by

Sort Order Select

Journal Articles

Addition by subtraction

Sonja Zweegman, Tanya M. Wildes

Blood (2021) 137 (22): 3005–3006.

https://doi.org/10.1182/blood.2021011144

Published: 2021

Journal Articles

How I treat cold agglutinin disease

Sigbjørn Berentsen

Blood (2021) 137 (10): 1295–1303.

https://doi.org/10.1182/blood.2019003809

Published: 2021

Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Blood (2019) 134 (Supplement_1): 695.

https://doi.org/10.1182/blood-2019-121694

Published: 2019

Journal Articles

Longitudinal Trajectory of Frailty in Blood or Marrow Transplant (BMT) Survivors - a BMT Survivor Study (BMTSS)

Mukta Arora, MD, Yanjun Chen, MS, Jessica Wu, MPH, Lindsey Hageman, MPH, Emily Ness, MPH, Michelle Kung, MA, Liton F. Francisco, BS, Alysia Bosworth, BA, Daniel J. Weisdorf, MD, Stephen J Forman, MD, Wendy Landier, PhD CRNP, Merve - Pamukçuoğlu, MD, Saro H. Armenian, DO, MPH, Lennie Wong, PhD, Smita Bhatia, MDMPH

Blood (2019) 134 (Supplement_1): 699.

https://doi.org/10.1182/blood-2019-123344

Published: 2019

Journal Articles

Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors

Blood (2019) 134 (Supplement_1): 1649.

https://doi.org/10.1182/blood-2019-127029

Published: 2019

Journal Articles

Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients

Nicola Polverelli, Paolo Tura, Giorgia Battipaglia, MD, Gandolfi Lisa, Tatiana Zollner, MD, Michele Malagola, MD, Enrico Morello, MD, Alessandro Turra, MD, Simona Bernardi, PhD, Camilla Zanaglio, PhD, Federica Re, Mohamad Mohty, MD PhD, Domenico Russo, MD

Blood (2019) 134 (Supplement_1): 41.

https://doi.org/10.1182/blood-2019-127026

Published: 2019

Journal Articles

Validation of SIE, Sies, GITMO Operational Criteria for the Definition of Fitness in Elderly Patients Affected with Acute Myeloid Leukemia: A Six-Years Retrospective Real-Life Experience

Raffaele Palmieri, MD, Giovangiacinto Paterno, Eleonora De Bellis, Elisa Buzzatti, Valentina Rossi, Ambra Di Veroli, MD, Fabiana Esposito, Lisa Mercante, Carmelo Gurnari, MD, Paola Casciani, Maria Ilaria Del Principe, Luca Maurillo, Maria Teresa Voso, MD, William Arcese, Adriano Venditti, Francesco Buccisano, MD

Blood (2019) 134 (Supplement_1): 2150.

https://doi.org/10.1182/blood-2019-127873

Published: 2019

Journal Articles

Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials

Smith Giri, MBBS, Madan R Aryal, MD, Han Yu, PhD, Alyssa Grimshaw, MSLIS, Ranjan Pathak, MD, Scott F. Huntington, MD MPH, Binod Dhakal, MBBS

Blood (2019) 134 (Supplement_1): 2188.

https://doi.org/10.1182/blood-2019-130389

Published: 2019

Journal Articles

Venetoclax and DLI for Patients with Early Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. a Historical Prospective Multicenter Trial

Odelia Amit, MD, Yael Bar-On, MD, Galit Perets, MD, Lena Atlas, Liat Shargian, MD, Moshe Yeshurun, MD, Bruria Yachini, RN, Chen Karni, RN, Ron Ram, MD

Blood (2019) 134 (Supplement_1): 2018.

https://doi.org/10.1182/blood-2019-126999

Published: 2019

Journal Articles

A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE)

Thierry Facon, MD, Jesús San-Miguel, Saad Z. Usmani, MD, Meletios A. Dimopoulos, MD, Shaji K. Kumar, MD, Maria-Victoria Mateos, Michele Cavo, Bart Heeg, PhD, Sophie Van Beekhuizen, MSc, Marta Pisini, MBA, Sandhya Nair, Annette Lam, BSc, MSc, Mary Slavcev, Jianming He, PhD

Blood (2019) 134 (Supplement_1): 2144.

https://doi.org/10.1182/blood-2019-123561

Published: 2019

Journal Articles

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Shannon R. McCurdy, MD, Shannon H. Gier, BS, Daria V. Babushok, MD PhD, Noelle V. Frey, MD, Saar I. Gill, MD PhD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Alexander E. Perl, MD, Ivan Maillard, MD PhD, Keith W. Pratz, MD, David L. Porter, MD, Martin P. Carroll, MD, Phyllis A. Gimotty, PhD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 2209.

https://doi.org/10.1182/blood-2019-124468

Published: 2019

Journal Articles

Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults with Multiple Myeloma to Drive Personalized Treatment Decisions

Nitya Nathwani, MD, Supriya G. Mohile, MD MS, Sandra Kurtin, PhD, ANP-C, AOCN, Debra Wujcik, PhD, Susie Owenby, Matthew Dudley, William Dudley, PhD, Tanya M. Wildes, MD

Blood (2019) 134 (Supplement_1): 3443.

https://doi.org/10.1182/blood-2019-130245

Published: 2019

Journal Articles

The Revised Myeloma Comorbidity Index (R-MCI) As a Promising Approach for Predicting Overall (OS)- and Progression-Free (PFS) Survival and Optimizing Therapy Strategies in Multiple Myeloma (MM) Patients (pts) - Comparative Analysis of 5 Comorbidity Indices (CI), Including Retro- and Prospective Applicability

Katja Schoeller, Gabriele Ihorst, Sophia Scheubeck, Max Holler, Sandra M. Woerner, Heike Reinhardt, Stefan P. Müller, Justus Duyster, MD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2019) 134 (Supplement_1): 3474.

https://doi.org/10.1182/blood-2019-127030

Published: 2019

Journal Articles

Frailty in Older Adults with Multiple Myeloma: A Study of United States Veterans

Bindiya Patel, MD, Suhong Luo, MPH, Tanya M. Wildes, MD, Kristen M. Sanfilippo, MD MPHS

Blood (2019) 134 (Supplement_1): 3478.

https://doi.org/10.1182/blood-2019-124971

Published: 2019

Journal Articles

Correlation between Changes in Granzyme B Expression and Time to Progression in Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide and Dexamethasone Therapy

Takahiro Kobayashi, MD PhD, Yuki Fujioka, MD PhD, Sho Ikeda, MD PhD, Hiroyoshi Nishikawa, MD PhD, Naoto Takahashi, MD PhD

Blood (2019) 134 (Supplement_1): 1792.

https://doi.org/10.1182/blood-2019-125649

Published: 2019

Journal Articles

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Ajai Chari, MD, Dorothy Romanus, RPh, PhD, Aditya Raju, Lauren Cain, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 1827.

https://doi.org/10.1182/blood-2019-121658

Published: 2019

Journal Articles

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

Blood (2019) 134 (Supplement_1): 1887.

https://doi.org/10.1182/blood-2019-125749

Published: 2019

Journal Articles

Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Guido Gini, MD, Monica Tani, Alessandra Tucci, MD, Renato Bassan, MD, Filippo Ballerini, MD, Michela Sampaolo, Francesco Merli, MD, Francesca Re, Attilio Olivieri, Ombretta Annibali, Anna Marina Liberati, Carlo Visco, Annalisa Arcari, MD, Sergio Storti, MD, Alberto Fabbri, MD, Gerardo Musuraca, MD, Vittorio Ruggero Zilioli, MD, M. Christina Cox, MD PhD, Stefano Luminari, MD

Blood (2019) 134 (Supplement_1): 2880.

https://doi.org/10.1182/blood-2019-126568

Published: 2019

Journal Articles

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Blood (2019) 134 (Supplement_1): 982.

https://doi.org/10.1182/blood-2019-129618

Published: 2019

Journal Articles

Anticoagulation Challenges in Hematogeriatrics: Effectiveness and Safety of Direct Oral Anticoagulants Vs Vitamin k Antagonist in Elderly with Atrial Fibrillation

Desirée Campoy, MD, Gonzalo Artaza, MD, César A Velasquez, MD, Tania Canals, MD, Erik A Johansson, MD, Katia Flores, MD, Gabriela Bastidas, MD, Silvia Ruiz, MD, Gabriela S Ene, MD PhD, Alessandra Comai, MD, Maricel Subira, MD PhD, Ramón Salinas, MD PhD, Jorge Sierra, MD, Pável E Olivera, MD

Blood (2019) 134 (Supplement_1): 1162.

https://doi.org/10.1182/blood-2019-125150

Published: 2019

NARROW

Addition by subtraction

How I treat cold agglutinin disease

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Longitudinal Trajectory of Frailty in Blood or Marrow Transplant (BMT) Survivors - a BMT Survivor Study (BMTSS)

Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors

Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients

Validation of SIE, Sies, GITMO Operational Criteria for the Definition of Fitness in Elderly Patients Affected with Acute Myeloid Leukemia: A Six-Years Retrospective Real-Life Experience

Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials

Venetoclax and DLI for Patients with Early Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. a Historical Prospective Multicenter Trial

A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE)

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults with Multiple Myeloma to Drive Personalized Treatment Decisions

Frailty in Older Adults with Multiple Myeloma: A Study of United States Veterans

Correlation between Changes in Granzyme B Expression and Time to Progression in Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide and Dexamethasone Therapy

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Anticoagulation Challenges in Hematogeriatrics: Effectiveness and Safety of Direct Oral Anticoagulants Vs Vitamin k Antagonist in Elderly with Atrial Fibrillation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only